Borneol-modified PEGylated graphene oxide as a nanocarrier for brain-targeted delivery of ginsenoside Rg1 against depression
Authors:
- 30 July 2023
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 643, 123284
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Distributive and Quantitative Analysis of the Main Active Saponins in Panax notoginseng by UHPLC-QTOF/MS Combining with Fluorescence Microscopy and Laser MicrodissectionPlanta Medica, 2016
- Neurotrophic factors in depression in response to treatmentJournal of Affective Disorders, 2015
- Delivery of Paclitaxel Using PEGylated Graphene Oxide as a NanocarrierACS Applied Materials & Interfaces, 2014
- Covalent Functionalization of Graphene Oxide with Biocompatible Poly(ethylene glycol) for Delivery of PaclitaxelACS Applied Materials & Interfaces, 2014
- Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulationsBiomaterials, 2014
- PEGylated graphene oxide as a nanocarrier for podophyllotoxinJournal of Nanoparticle Research, 2014
- Graphene and graphene oxide as new nanocarriers for drug delivery applicationsActa Biomaterialia, 2013
- PEGylated Graphene Oxide-Mediated Protein Delivery for Cell Function RegulationACS Applied Materials & Interfaces, 2012
- Engineered Redox‐Responsive PEG Detachment Mechanism in PEGylated Nano‐Graphene Oxide for Intracellular Drug DeliverySmall, 2012
- Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depressionMolecular Psychiatry, 2011